sihuan pharmaceutical holdings group ltd. - SHPHF

SHPHF

Close Chg Chg %
0.21 -0.04 -19.16%

Open Market

0.17

-0.04 (19.16%)

Volume: 50.00K

Last Updated:

Jan 8, 2026, 9:30 AM EDT

Company Overview: sihuan pharmaceutical holdings group ltd. - SHPHF

SHPHF Key Data

Open

$0.17

Day Range

0.17 - 0.17

52 Week Range

0.09 - 0.21

Market Cap

$1.55B

Shares Outstanding

9.13B

Public Float

4.10B

Beta

-1.57

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

$0.08

Yield

82.28%

Dividend

$0.00

EX-DIVIDEND DATE

Sep 26, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

4.82K

 

SHPHF Performance

1 Week
 
0.00%
 
1 Month
 
-18.15%
 
3 Months
 
277.78%
 
1 Year
 
N/A
 
5 Years
 
N/A
 

SHPHF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About sihuan pharmaceutical holdings group ltd. - SHPHF

Sihuan Pharmaceutical Holdings Group Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Medical Aesthetic Products, Innovative Medicine and Other Medicine, and Generic Medicine. The Medical Aesthetic Products refers to the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care and others to provide non- or minimally invasive medical aesthetics comprehensive solutions. The company was founded by Feng Sheng Che and Wei Cheng Guo in 2001 and is headquartered in Beijing, China.

SHPHF At a Glance

Sihuan Pharmaceutical Holdings Group Ltd.
22nd floor, Building 4
Beijing, Beijing 100025
Phone 86-10-52278700 Revenue 264.16M
Industry Pharmaceuticals: Other Net Income -30,105,251.10
Sector Health Technology 2024 Sales Growth 0.593%
Fiscal Year-end 12 / 2025 Employees 2,667
View SEC Filings

SHPHF Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 2.98
Price to Book Ratio 1.311
Price to Cash Flow Ratio 16.28
Enterprise Value to EBITDA -20.95
Enterprise Value to Sales 1.776
Total Debt to Enterprise Value 0.285

SHPHF Efficiency

Revenue/Employee 99,047.498
Income Per Employee -11,288.058
Receivables Turnover 1.477
Total Asset Turnover 0.172

SHPHF Liquidity

Current Ratio 1.727
Quick Ratio 1.565
Cash Ratio 1.171

SHPHF Profitability

Gross Margin 61.468
Operating Margin -21.445
Pretax Margin -21.727
Net Margin -11.397
Return on Assets -1.962
Return on Equity -4.919
Return on Total Capital -4.108
Return on Invested Capital -4.098

SHPHF Capital Structure

Total Debt to Total Equity 22.338
Total Debt to Total Capital 18.26
Total Debt to Total Assets 9.274
Long-Term Debt to Equity 18.168
Long-Term Debt to Total Capital 14.851
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Sihuan Pharmaceutical Holdings Group Ltd. - SHPHF

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
510.33M 323.92M 262.60M 264.16M
Sales Growth
+42.94% -36.53% -18.93% +0.59%
Cost of Goods Sold (COGS) incl D&A
130.67M 116.50M 89.67M 101.79M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
46.74M 53.69M 30.62M 34.26M
Depreciation
41.80M 48.21M 27.74M 29.27M
Amortization of Intangibles
4.95M 5.48M 2.87M 4.99M
COGS Growth
+64.05% -10.85% -23.03% +13.51%
Gross Income
379.65M 207.42M 172.93M 162.37M
Gross Income Growth
+36.88% -45.37% -16.63% -6.11%
Gross Profit Margin
+74.39% +64.03% +65.85% +61.47%
2021 2022 2023 2024 5-year trend
SG&A Expense
313.68M 277.57M 200.21M 219.02M
Research & Development
134.60M 139.09M 81.53M 65.85M
Other SG&A
179.08M 138.48M 118.67M 153.17M
SGA Growth
+36.36% -11.51% -27.87% +9.40%
Other Operating Expense
- - - -
-
Unusual Expense
20.16M 241.58M (18.60M) (457.70K)
EBIT after Unusual Expense
45.81M (311.72M) (8.67M) (56.19M)
Non Operating Income/Expense
72.64M 39.85M 31.50M 37.00M
Non-Operating Interest Income
25.42M 21.80M 20.88M 24.39M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
18.50M 31.36M 38.01M 38.20M
Interest Expense Growth
+1,453.96% +69.52% +21.22% +0.49%
Gross Interest Expense
18.50M 31.64M 38.29M 38.41M
Interest Capitalized
- 275.48K 270.57K 210.51K
Pretax Income
99.95M (303.24M) (15.19M) (57.40M)
Pretax Income Growth
-11.43% -403.38% +94.99% -277.79%
Pretax Margin
+19.59% -93.61% -5.79% -21.73%
Income Tax
39.27M 29.23M 13.61M 6.01M
Income Tax - Current - Domestic
45.06M 14.62M 8.49M 15.10M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(5.79M) 14.60M 5.12M (9.09M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
36.09M (344.47M) (36.37M) (65.52M)
Minority Interest Expense
(28.49M) (54.94M) (28.75M) (35.42M)
Net Income
64.58M (289.53M) (7.62M) (30.11M)
Net Income Growth
-11.30% -548.31% +97.37% -294.87%
Net Margin Growth
+12.65% -89.38% -2.90% -11.40%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
64.58M (289.53M) (7.62M) (30.11M)
Preferred Dividends
- - - -
-
Net Income Available to Common
64.58M (289.53M) (7.62M) (30.11M)
EPS (Basic)
0.0068 -0.031 -0.0008 -0.0032
EPS (Basic) Growth
-11.69% -555.88% +97.42% -300.00%
Basic Shares Outstanding
9.43B 9.33B 9.30B 9.27B
EPS (Diluted)
0.0068 -0.031 -0.0008 -0.0032
EPS (Diluted) Growth
-11.69% -555.88% +97.42% -300.00%
Diluted Shares Outstanding
9.48B 9.33B 9.30B 9.27B
EBITDA
112.71M (16.46M) 3.34M (22.39M)
EBITDA Growth
+31.43% -114.60% +120.31% -769.82%
EBITDA Margin
+22.09% -5.08% +1.27% -8.48%

Sihuan Pharmaceutical Holdings Group Ltd. in the News